Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights ...

For a more detailed discussion of Aduro's Q3 2025 results, please refer to the Company's condensed interim consolidated financial statements and interim management discussion & analysis for the three ...

A growing number of manufacturers are restructuring in response to shrinking margins, supply chain disruptions, and ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

Semarion's SemaCyte® technology transforms adherent cell assays, enabling faster, automated workflows that enhance ...

Recursion Pharmaceuticals RXRX announced that it has dosed the first patient in its early-stage study of investigational ...

This photo taken on March 31, 2025 shows the exhibition booth of Invest in China at Hannover Messe 2025 in Hannover, Germany.

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Learn more ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Cradle Bio uses generative AI to help biologists design improved proteins and accelerate research ... with pharmaceutical and biotech companies such as Janssen, Merck, Pfizer, Servier, Ono, and Teijin ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...